Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer.
about
CDK1 promotes cell proliferation and survival via phosphorylation and inhibition of FOXO1 transcription factorEffects of Brassicaceae Isothiocyanates on Prostate CancerCheckpoint Kinase 2 Negatively Regulates Androgen Sensitivity and Prostate Cancer Cell Growth.Androgens upregulate Cdc25C protein by inhibiting its proteasomal and lysosomal degradation pathwaysOverexpression of CDC25B, CDC25C and phospho-CDC25C (Ser216) in vulvar squamous cell carcinomas are associated with malignant features and aggressive cancer phenotypesWidespread alternative exon usage in clinically distinct subtypes of Invasive Ductal CarcinomaThe cyclin-like protein Spy1/RINGO promotes mammary transformation and is elevated in human breast cancerS100A8/A9 (calprotectin) negatively regulates G2/M cell cycle progression and growth of squamous cell carcinoma.Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells.Inhibition of cyclin-dependent kinase phosphorylation of FOXO1 and prostate cancer cell growth by a peptide derived from FOXO1.CDC25 phosphatases in cancer cells: key players? Good targets?Phosphatases and kinases regulating CDC25 activity in the cell cycle: clinical implications of CDC25 overexpression and potential treatment strategiesInsulin-Like Growth Factor-1 Receptor Deficiency in Macrophages Accelerates Atherosclerosis and Induces an Unstable Plaque Phenotype in Apolipoprotein E-Deficient Mice.Posttranslational modification of the androgen receptor in prostate cancer.AR, the cell cycle, and prostate cancer.Inhibitors of Cdc25 phosphatases as anticancer agents: a patent review.Targeting CDC25C, PLK1 and CHEK1 to overcome Docetaxel resistance induced by loss of LZTS1 in prostate cancer.The AR dependent cell cycle: mechanisms and cancer relevance.The regulatory roles of phosphatases in cancer.Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex.miR-142-3p inhibits cancer cell proliferation by targeting CDC25C.Genotoxic stress modulates CDC25C phosphatase alternative splicing in human breast cancer cell lines.Reactive-oxygen-species-mediated Cdc25C degradation results in differential antiproliferative activities of vanadate, tungstate, and molybdate in the PC-3 human prostate cancer cell line.Gossypin induces G2/M arrest in human malignant glioma U251 cells by the activation of Chk1/Cdc25C pathway.Differential expression of CDC25 phosphatases splice variants in human breast cancer cells.G2/M accumulation in prostate cancer cell line PC-3 is induced by Cdc25 inhibitor 7-chloro-6-(2-morpholin-4-ylethylamino) quinoline-5, 8-dione (DA 3003-2).lncRNA HOXD-AS1 Regulates Proliferation and Chemo-Resistance of Castration-Resistant Prostate Cancer via Recruiting WDR5.Induction of the adenoma-carcinoma progression and Cdc25A-B phosphatases by the trefoil factor TFF1 in human colon epithelial cells.Aberrant pre-mRNA splicing of a highly conserved cell cycle regulator, CDC25C, in myelodysplastic syndromes.
P2860
Q24321230-56638988-77E5-430A-9BB3-3073A11EDFB2Q26749086-F24375D1-95B3-4A2A-92A4-E0B8032D61B9Q28395484-DD657D23-45E4-4604-BF0D-5E49DACED4EEQ28397032-C2836926-6CCF-437C-97C0-E0B5BC784114Q33586710-9335117A-ED27-4246-994C-0F56D80FDC56Q33911898-688B9F6B-81C0-4445-A4B1-45FDE13AD62FQ34142075-608FFFEE-3C10-4BAF-8BE5-52E6B44BFF25Q34854105-FA361256-F6EC-4DCE-A7D9-5443D2FD6BA4Q35127580-E68722B6-B084-478E-853F-9DDB8E22A816Q35214798-1424244A-D59D-4A22-AC46-0315C1DCA892Q35238068-FA205BE8-FEAC-4996-A218-5044EB4EA07CQ36849329-85C5950E-2CDC-41BF-8D86-4AEC00DE1466Q36889310-BF7201FD-5BBE-4DAD-9357-546DB67280B8Q36984213-F4459173-80C5-4ECA-A41A-1771E933EC11Q37092022-928E71A4-9561-4A17-9B0A-6D20882CAC32Q37095260-E0D02385-FC34-495A-81AE-4519CB17E066Q37694564-57E8F4DA-55C9-4144-BD15-18464E831539Q37718444-C5498C49-CC38-478D-8545-74F7A74C0913Q37904028-D856A9E4-A035-40D6-81E0-583ED5B240A7Q38090432-F668DC6B-D25A-4B44-A088-5FF065887A6BQ38310745-89D92046-69C9-4A22-8231-361923FEC79EQ38799902-4D9CF9BB-D31C-480D-B653-3B1BE7069C47Q39301082-E6C08782-6DEE-4B5B-9B49-AF00977D39C5Q39455819-35DC96BF-15C4-4F01-92B2-AB9F569AAE0DQ39460930-E05B34E6-2EFA-4F33-B1A3-D66C51A2C7F0Q39524071-F1442745-AF75-492C-A98A-693DE6D951ADQ39687262-EBC3721D-FBAB-42BC-9B99-C4B1FD92964DQ52771926-7370E26F-22FB-40C9-9E19-34071FDD2336Q53345922-F7C03C8A-E64C-457F-93ED-DF1454708D1DQ53478733-36917399-E89E-47F5-A1D8-E31CB738D79B
P2860
Increased expression and activity of CDC25C phosphatase and an alternatively spliced variant in prostate cancer.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Increased expression and activ ...... ed variant in prostate cancer.
@en
type
label
Increased expression and activ ...... ed variant in prostate cancer.
@en
prefLabel
Increased expression and activ ...... ed variant in prostate cancer.
@en
P1476
Increased expression and activ ...... ced variant in prostate cancer
@en
P2093
Michael Ittmann
P304
P356
10.1158/1078-0432.CCR-04-2551
P407
P50
P577
2005-07-01T00:00:00Z